The disadvantage of investigating IL-6 responsiveness at day +90 is that some patients develop late acute GVHD during a further reduction in immunosuppression; analysis of samples collected at this time point thus captures most, but not all, patients developing acute GVHD. The gene discussed is IL6; the disease is acute graft versus host disease.